Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 25

1.

Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme.

Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, Yusuf S, Pocock S; CHARM Investigators and Committees.

Lancet. 2003 Sep 6;362(9386):759-66. Erratum in: Lancet. 2009 Nov 21-2009 Nov 27;(9703):1744.

PMID:
13678868
2.

Angiotensin inhibition in heart failure.

McMurray JJ.

J Renin Angiotensin Aldosterone Syst. 2004 Sep;5 Suppl 1:S17-22. Review.

PMID:
15526237
3.
4.

[CHARM study--new strategy for the treatment of heart failure].

Hasegawa H, Komuro I.

Nihon Rinsho. 2004 May;62(5):995-1002. Review. Japanese.

PMID:
15148833
5.

[Benefits of candesartan in the treatment of symptomatic heart failure--CHARM programme].

Umemoto S, Matsuzaki M.

Nihon Rinsho. 2004 Jan;62(1):211-8. Review. Japanese.

PMID:
14737855
7.

Candesartan for the treatment of hypertension and heart failure.

Ostergren J.

Expert Opin Pharmacother. 2004 Jul;5(7):1589-97. Review.

PMID:
15212609
8.

Exploring new treatment strategies in heart failure.

Swedberg K.

Blood Press Suppl. 2000;1:44-8. Review.

PMID:
11059637
9.

[Effect of angiotensin II receptor antagonist on heart failure].

Matsumori A.

Nihon Rinsho. 2004 Jan;62(1):203-10. Review. Japanese.

PMID:
14737854
10.

Angiotensin receptor blockers in heart failure.

Stergren J, McMurray JJ.

J Renin Angiotensin Aldosterone Syst. 2003 Sep;4(3):171-5. Review.

PMID:
14608522
11.

The CHARM program: the effects of candesartan for the management of patients with chronic heart failure.

McKelvie RS.

Expert Rev Cardiovasc Ther. 2009 Jan;7(1):9-16. doi: 10.1586/14779072.7.1.9. Review.

PMID:
19105762
12.

Candesartan cilexetil in the treatment of chronic heart failure.

Baguet JP, Barone-Rochette G, Neuder Y.

Vasc Health Risk Manag. 2009;5(1):257-64. Epub 2009 Apr 8. Review.

13.

ACE inhibitors in heart failure: what more do we need to know?

Demers C, Mody A, Teo KK, McKelvie RS.

Am J Cardiovasc Drugs. 2005;5(6):351-9. Review.

PMID:
16259523
14.

Improving outcomes in chronic heart failure.

Komajda M.

Drugs Today (Barc). 2006 Dec;42 Suppl C:29-36. Review.

PMID:
17245479
15.

Candesartan cilexetil: a review of its use in the management of chronic heart failure.

Fenton C, Scott LJ.

Drugs. 2005;65(4):537-58. Review.

PMID:
15733014
16.

Clinical efficacy and tolerability of candesartan cilexetil. Candesartan Study Groups in Japan.

Ogihara T, Arakawa K.

J Hum Hypertens. 1999 Jan;13 Suppl 1:S27-31; discussion S33-4. Review.

PMID:
10076918
17.

Candesartan for the management of heart failure: more than an alternative.

McKelvie RS.

Expert Opin Pharmacother. 2006 Oct;7(14):1945-56. Review.

PMID:
17020420
18.

Candesartan cilexetil: a pharmacoeconomic review of its use in chronic heart failure and hypertension.

Plosker GL, Keam SJ.

Pharmacoeconomics. 2006;24(12):1249-72. Review.

PMID:
17129078
19.

Candesartan in heart failure.

Ripley TL, Chonlahan JS, Germany RE.

Clin Interv Aging. 2006;1(4):357-66. Review.

20.

[AII antagonists (candesartan and irbesartan) in the treatment of cardiovascular diseases].

Spinar J, VĂ­tovec J.

Vnitr Lek. 2012 Oct;58(10):755-60. Review. Czech.

PMID:
23121062

Supplemental Content

Support Center